Morgan Stanley lowered the firm’s price target on Amwell (AMWL) to $6 from $10.50 and keeps an Equal Weight rating on the shares. For healthcare technology and providers, the firm sees an “attractive backdrop for alpha-generation opportunities” in 2026, the analyst tells investors. Meanwhile, managed care stocks have underperformed in 2025 and are facing “another year of unprecedented policy, reimbursement, and utilization headwinds,” the analyst added in a year-ahead outlook note for the Healthcare Services group.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMWL:
- Balanced Outlook on American Well: Optimism Amidst Caution with Strategic Shifts and Contract Dependencies
- Amwell management to meet virtually with BTIG
- Amwell’s Earnings Call: Mixed Results and Strategic Focus
- Amwell price target lowered to $7 from $10 at TD Cowen
- Amwell price target lowered to $6 from $8 at Stifel